TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune

Status Recruiting

Clinical Trial Summary

This prospective, open-label, nonrandomized, multicenter clinical trial aims at comparing the efficacy and safety of combined use of TPO-RAs with low-dose anti-CD20 monoclonal antibody vs. the best available therapy（BAT）in adult immune thrombocytopenia with autoantibodies failed (due to intolerance or resistance) to first-line treatment.

Clinical Trial Description

This is a prospective, open-label, nonrandomized, multicenter clinical trial aiming at comparing the efficacy and safety of combined use of TPO-RAs with low-dose anti-CD20 monoclonal antibody vs. the best available therapy（BAT）in adult immune thrombocytopenia (ITP) with autoantibodies failed (due to intolerance or resistance) to first-line treatment. The subjects include ITP secondary to connective tissue diseases (including but not limited to systemic lupus erythematosus, Sjogren's syndrome and rheumatoid arthritis), primary ITP with positive antinuclear antibody but not up to the diagnostic criteria of connective tissue diseases, primary Evans syndrome, Evans syndrome secondary to connective tissue diseases, and primary ITP with positive Coomb's test but not up to the diagnostic criteria of Evans syndrome. Adult ITP patients with autoantibodies (18-65 years) will be nonrandomly divided into the following two treatment groups: 1. combined use of TPO-RAs with low-dose anti-CD20 monoclonal antibody. 2. the best available therapy（BAT）other than combined use of TPO-RAs with low-dose anti-CD20 monoclonal antibody. The current treatment strategies and possible risks of combined use of TPO-RAs with low-dose anti-CD20 monoclonal antibody in the treatment of ITP with autoantibodies will be fully introduced to the patients by the researchers. Then the patients will be divided into one of the two groups according to the patients' will. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04915482
Study type	Interventional
Source	Institute of Hematology & Blood Diseases Hospital
Contact	Rongfeng Fu, MD
Phone	+862223909009
Email	furongfeng@ihcams.ac.cn
Status	Recruiting
Phase	Phase 2/Phase 3
Start date	June 6, 2021
Completion date	February 28, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04169100` - Novel Form of Acquired Long QT Syndrome	Phase 4
Enrolling by invitation	`NCT03683186` - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension	Phase 3
Active, not recruiting	`NCT03688191` - Study of Sirolimus in CTD-TP in China	Phase 4
Completed	`NCT00004357` - Absorption of Corticosteroids in Children With Juvenile Dermatomyositis	Phase 2
Recruiting	`NCT04918524` - The Clinical Features and Pregnancy Outcomes of CTD Patients
Recruiting	`NCT04993885` - Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies	Phase 2
Not yet recruiting	`NCT05998759` - Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia	Phase 2
Recruiting	`NCT05065814` - Connective Tissue Diseases and Vitamin D Deficiency	N/A
Completed	`NCT03494036` - Effect of Synbiotic on Immune Response, Gut Permeability and Microbiota in Patient With Connective Tissue Disease	N/A
Completed	`NCT03929120` - Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)	Phase 1
Completed	`NCT00001330` - Study of Silicone-Associated Connective Tissue Diseases	N/A
Not yet recruiting	`NCT05980728` - Connective Tissue Disease Patients With Pulmonary Hypertension
Not yet recruiting	`NCT04582292` - Laryngeal Manifestations of Connective Tissue Diseases
Completed	`NCT06458803` - Efficacy and Safety of Eltrombopag for Refractory Thrombocytopenia Associated With Connective Tissue Disease
Recruiting	`NCT03214263` - Identification of New Biomarkers to Promote Personalized Treatment of Patients With Inflammatory Rheumatic Diseases
Completed	`NCT04171362` - The Effect of Connective Tissue Massage in Patients With Migraine	N/A
Completed	`NCT02392130` - A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin	Phase 1
Completed	`NCT01656278` - An MRI-guided Treatment Strategy to Prevent Disease Progression in Patients With Rheumatoid Arthritis	N/A
Recruiting	`NCT05505409` - Efficacy and Safety of Pirfenidone in CTD-ILD	Phase 4
Recruiting	`NCT02768259` - Prevalence of Pulmonary Arterial Hypertension in Patients With Connective Tissue Diseases in Egyptian Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms